US INVESTOR PRESENTATION

21-31 July 2015

Mission:
- Launch the first FDA approved objective, quantitative, diagnostic test for depression
- Commercial launch of the first objective, quantitative test for stress for the corporate and consumer market

Vision:
- Transform the assessment and management of Mental Health using our proprietary technology

Ripe for Disruption:
"It is critical to realise that we cannot succeed if we use DSM categories as the gold standard" - "We need a quantitative method for diagnosing depression" (U.S. National Institute of Mental Health - May 2013)

Strategic Partners:
- Johns Hopkins University and the Black Dog Institute
- World leaders in mental health research

BLACK DOG INSTITUTE
Because everyone deserves peace of mind

JOHNS HOPKINS
MEDICINE
SCHOOL OF MEDICINE

Valuation:
- Capitalisation $30m
- 90M shares @ $0.33

Our 5 Year Goal:
- Workplace Stress market   US$100 million revenue
- Depression Diagnostic   US$60 million revenue
- Consumer App Market   tba

strong margins →

Significant Earnings

Medibio

350 Million Worldwide Diagnosed With Depression
1 Suicide Every 40 Seconds

1 Million Suicides
Every Year

26%
of Adult
Population

27%
of Adult
Population

20%
of Adult
Population

- 1 in 10 on Antidepressants
- $10Bn Spent annually
- Antidepressants prescribed in 70%
of PCP mental health visits

Global Cost $2.5T (2030 est. $6T) — Depression and Anxiety account for **+50%** of this burden

http://www3.weforum.org/docs
WEF_Harvard_HE_GlobalEconomicBurdenNonCommunicableDiseases_2011.pdf

Convergence of 2 Huge Industries

Information Technology

- **4.3% of US GNP**
- **$700 billion**

Healthcare

- **17.2% of US GNP**
- **$2.8 trillion**

Digital Health

- Medibio is not revenue dependent upon regulatory approval

- The sole new and credible method for the assessment of stress levels, easily translated to the workplace, wearable, and the App market

- This stress market can be accessed without regulatory approval

Medibio Limited

Advisory Board

DR JAMES CAMPBELL
Non Exec Director

KRIS KNAUER
Chief Executive Officer

CHRIS INDERMAUR
Chairman

DR MICHAEL PLAYER
COO

DR MATT MESNIK
CMO

STEVEN STAPELBERG
VP eHealth

SEAN MATHIESON
Chief Innovation Officer

ROBERT LEES
CFO & Co Sec

DR MATT FLAX
Head of Algorithm Development Team

CLAUDE SOLITARIO
Head Sales

PROF FRANK PREDERGAST
(Eli Lilly Company)

STEPHEN PEARCE
(Lions Eye Institute)

PROF HANS STAMPFER
(Inventor)

DR STEPHEN ADDIS
(Inventor)

- Comprehensive suite of patents covering the use of CHR technology for both:
  - medical diagnostics including assessment of treatment efficacy
  - stress assessment

- Patent suite for medical diagnostics includes:
  - "Method for Diagnosing Psychiatric Disorders"
  - USA(US624502), Canada, Australia, New Zealand, Israel

- Provisional Patents lodged in the US in June 2015:
  - "Method and System for Monitoring Stress Conditions" covering the use of CHR for stress assessment
  - "Method and System for using CHR to Diagnose Psychiatric Disorders" covering new discoveries in past 18 months

THE PROBLEM

- No objective test for mental illness

- The diagnostic "gold standard" is a clinical/expert opinion

- Diagnostic agreement between clinicians can vary considerably

- Misdiagnosis of depression (and other mental illness) places a huge cost burden on the healthcare system and the workplace

THE SOLUTION

- Quantitative, objective test

- Diagnosis based on patient's biological data (circadian heart rate)

- Simple, safe, quick, and unobtrusive

- Gives objective indication of treatment effectiveness

- Savings to the health system

- The autonomic nervous system (ANS) plays a key role in circadian sleep-wake regulation of physiological activity including heart rate

- Conventionally mental illness is associated with disturbances in ANS/circadian regulation

- Mental state-linked ANS disturbance is observed via the cardiovascular system during sleep when external influences are absent

- Analysis of circadian heart rates (CHR) gives objective indications of 'core' physiological differences between different forms of mental illness such as anxiety, depression, and stress

- MEB's technology based on over 15 years of research

- Different forms of mental illness such as anxiety and depression are associated with distinctly different patterns of CHR

- Distinct 'biomarkers' in heart rate data for depression and certain other mental illnesses

- CHR is 'state-dependent' - a change in clinical status is associated with a change in CHR patterns

- Serial monitoring of patients under psychiatric treatment showed that:

  - *effective intervention is associated with normalisation of CHR*
  - *ineffective intervention does not show normalisation*
 - *provides a tool for determining the treatment effectiveness*

- Sleep rates are visibly lower and less variable than awake rates.

- The onset of sleep and moment of waking show a clear change in the mean trend.

- Sleep and waking is usually brief and occurs quickly.

- Body movement data clearly correlates with heart rate, with a cessation of movement during the sleep period.

DEPRESSED INDIVIDUAL

ANXIETY DISORDER

- Depressed individual upon initial diagnosis
- Same individual after 18 days following effective intervention
  - Olanzapine – 10mg (night)
  - Mirtazapine – 60mg (night)
- Illustrates the 'state-dependent' nature - a change in clinical status is associated with a change in CHR patterns

ROAD TO VALIDATION

JOHNS HOPKINS (JHU) STUDY OBJECTIVE

- To validate the use of Medibio's CHR technology to differentiate between depressed and non-depressed individuals
- Designed to provide clinical data to support FDA certification of Medibio's proprietary depression test

STUDY TIMELINE

- Anticipated results published in Q4 2015
- Simple, quick, powered to only need 80-100 participants

BLACK DOG INSTITUTE STUDY OBJECTIVE

- To demonstrate that CHR Technology distinguishes between melancholic and non-melancholic depression and also determine treatment response.

STUDY TIMELINE

- Anticipated results published in Q4 2015
- Simple, quick, powered to only need 60-80 participants

THREE CLEARLY DEFINED MARKETS

CLINICAL

NON-CLINICAL (Stress)

MEDICAL
(US$30Bn)

Primary Care Physicians

Psychiatrists

Psychologists

Therapists

Counsellors

Cardiologists

CORPORATE
(US$19Bn)

High Risk Occupations
- Defence
- Police
- Fire/Emergency

Insurance Companies

Corporate Wellness

Professions

Elite Sports

CONSUMER
(US$26Bn)

App Stores

Insurance Companies

Wellness

Digital Health

Companies

Clinician orders test

No disruption to normal clinical work flow

Secure access to Diagnostic Reporting and Analysis – Anywhere/Anytime

CHR collected from Patient and transmitted to HIPAA compliant Cloud Storage

CHR processed by machine learning algorithms Biometric data stored in HIPAA compliant cloud

- 63 million annual ambulatory care visits in the US for mental health
  - 21 million to PCP's (30% of PCP's patients are treated for a psychiatric condition)
  - 31 million to Medical Specialists (psychiatrists/psychologists)

- PCP's are becoming the primary psychiatric care provider [1] (7% of all PCP visits involve prescribing of antidepressants)
  - 40% receive only psychiatric medication
  - 30% receive medication and are referred for therapy
  - 17% referred to a psychiatrist
  - 12% referred to a psychologist

- PCP Initial diagnostic market – 21 million annual PCP visits @ $45 ~ $1 billion annually

- Ongoing monitoring - 16 million with depression in US quarterly [2] @ $22.50 ~ $1.6 billion annually

- Identified a series of existing CPT™ codes and payment structures which are supportive of, and can likely be leveraged for, MEB's business plan in the US

Medicare		Private	Insurance	Assumption
93225	Recoding (Provider)	$26.87	$40	
93226	Analysis with Report (Medibio)	$37.97	$57	$45
93227	Physician review & Interpretation (Provider)	$26.87	$40	

- Cloud based analysis and reporting = minimal costs per report

1. NIH – Mental health in family Medicine 2010 Mar7(1)
2. CDC

- Stress leads to changes in autonomic regulation that are reflected in 'deviations' in CHR patterns

- MEB's technology provides an objective measure of the impact of stress on wellbeing via

    - the type and degree of deviation from normal CHR

    - the diagnostic significance of the deviation

- employees are classified into one of three distinct categories.

    – 'green' - normal to mild (no immediate action needed)

    – 'amber' - moderate (the impact of stress on wellbeing is approaching unhealthy levels)

    – 'red' - severe (the impact of stress may have an unhealthy impact on wellbeing (recommend lifestyle changes)

- the intervention will be tailored to the individual employee based on the results of their stress assessment from the CHR technology.

STRESS-RELATED WORSENING IN CIRCADIAN PATTERN

MIDDLE AGED MAN ACTING IN SENIOR EXECUTIVE POSITION

	24HR Mean	SLEEP mean
	67	57
	74	65

- before senior position
- 6 months later

DEMAND IN THE US DRIVEN BY MANY FACTORS

- 43% of the adults in the US suffer adverse health effects from stress
- stress is estimated to cost US employees $300 billion annually
- over half of the 550 million working days lost annually in the U.S. from absenteeism are stress related[1])
- Harvard estimate 60-90% of doctor's visits are caused by stress[2]
- need to reduce health care spend
- social responsibility/OHS Requirements

US MARKET SIZE

- 54 million employees in the US (+1,000 staff firms[3])
- 90% of corporates have an existing wellness program
- Annual wellness spend $100-$500 per employee
- US$2.5Bn revenue potential annually

GO TO MARKET STRATEGY

- partner with existing participants in the Corporate Wellness market
- Medibio will provide data analytics and reporting - our core competency

1. www.stress.org/workplace-stress,
2. www.evancarmichael.com/Work-Life/1877/Less-Stress-More-Profit--the-Value-of-Corporate-Stress-Management-Training.html
3. US Census

Preventice

Employee fitted with heart monitor and records ECG data over a 10-12 hour period

ECG Data is stored on HIPAA Compliant Cloud-based Platform and can be coded to protect the individuals identity

ECG Data is processed for diagnosis and results are stored on HIPAA Compliant Cloud-based Platform

Corporate Report

"Stress Dashboard"

de-identified statistical summary of the overall results

Employee Report

"Individualised Report" (assessed stress level) and support/education based on stress level

CORPORATE DASHBOARD AND WIREFRAMES

The management dashboard

The dashboard will enable management to track their employee progress in reducing stress through the program.

The dashboard can be configured to display aggregated information that is of importance such as:

- What is the stress profile of the workforce?
- How successful have the wellness initiatives been in reducing stress in the workplace?

Example Client Dashboard: Client 5 overview: Static state.

ASSESSMENT

Enable employees to check their stress levels

Personal early warning system for people at risk

Prevention is better than cure

SUPPORT

Provide educational material, support, and intervention based on their stress level

May recommend discussion with PCP

Provide the ability to conduct on-going monitoring to check progress

EMPLOYER BENEFIT

Metrics on stress levels for job classes and types

Reduced absenteeism and increased productivity

Reduced claims and pressure on the health care systems

END TO END SOLUTION

- All Apps related to stress/mental health are:

  - based on reducing tension via breathing, yoga, and relaxing sounds

  - wellness products not stress identification and management

  - mental health Apps are based on a digitised version of the DSM

  - none offer objective stress assessment based on extended research

- Medibio's App:

  - Based on 15 years of medical research which is currently being validated by Johns Hopkins University and Black Dog Institute

  - An objective, health sector endorsed, objective stress assessment application and management tool

  - Ability to compare this test with previous scans run to check progress

 - Best in class intervention tailored to your stress level

  1. Source – Technology News.com.au
 2. Accenture Digital Consumer Tech Survey 2014

Timing	Milestone	Status
Q1 2015	Establish World-Class Advisory Board (Dr Prendergast)	✓
Q2 2015	Acquire remaining patents covering the technology (USA/Canada)	✓
	Complete beta testing of Stress Algorithms and lodge patent applications	✓
	Strategic Device Partner	✓
	Additional patent coverage on medical diagnostics	✓
Q3 2015	Corporate Stress Commercial Pilot	
	Announcement of foundation customers	
	Pre-submission package delivered to the FDA and FDA feedback	
	Complete development of Corporate Stress product	
	Commercial launch of Corporate Stress product	
Q4 2015	Results from US/Australian validation studies published	
	Commercial launch of Consumer Stress App (subject to device)	

TIMELINE TO COMMERCIALISATION

| Dec 14 | Mar 15 | Jun 15 | Dec 15 | Mar 16 | Jun 16 |

| Johns Hopkins Study | US Validation Study | | Completion & Publication | FDA (approval Targeted within 12 months) | Anxiety Panic Disorder Study |

| Black Dog Study | Australian Validation Study | | Completion & Publication | FDA (approval Targeted within 12 months) | Anxiety Panic Disorder Study |

| Corporate Stress Product | Workplace Stress Product Development | Stress Product Launch | First Revenue |

This presentation does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law. Persons needing advice should consult their stockbroker, bank manager, solicitor, accountant or other independent financial advisor.

Certain statements made in this presentation are forward-looking statements. These forward looking statements are not historical facts but rather are based on Medibio Limited's current expectations, estimates and projections about the industry in which Medibio operates, and its beliefs and assumptions.

Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements and should be considered at-risk statements. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services.

These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Medibio, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements.

Medibio cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Medibio only as of the date of this presentation. The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made.

Medibio will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

APPENDIX 1 - CAPITAL STRUCTURE

	Shares	Options	Description
Currently Issued	90.1 million	15,000,000 (Ex $0.10 unlisted) 6,667,000 (Ex $0.30 unlisted)	
Vendor Milestone 1	6,000,000	nil	(VALIDATION)
Vendor Milestone 2	6,000,000	nil	(ALGORITHIM)
Vendor Milestone 3	6,000,000	nil	FDA/CE MARK APPROVAL
ALL MILESTONES ACHIEVED	**108.1 million**	**21.7 million**	
Escrowed Shares	25,537,500		escrowed for 12 months
Board/Management Ownership	38,671,470		includes escrowed shares above
Top 20 Shareholders	63,330,745		(70.3%)